6 completed, 4 unknown, 2 recruiting, 1 enrolling by invitation. 4 Phase 2, 4 Phase 4, 2 Not applicable, 2 Phase 3, 1 Early Phase 1.
Follow Tofacitinib 5 MG: new trials by email Literature Review of Tofacitinib 5 MG trials Research Report on Tofacitinib 5 MG
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Major Adverse Cardiovascular Events (MACE) in Rheumatoid Arthritis Patient With Moderate to Severe Disease Activity Treated With Tofacitinib and Statins vs TNF Inhibitors: TOFSTAT CLINICAL TRIAL Tofacitinib 5 MG - Rheumatoid Arthritis, Major Adverse Cardiac Events | Phase 4 | Recruiting | Shaikh Zayed Hospital, Lahore | 120 | 2025-12-06 | 2026-04-28 |
| Efficacy and Safety of Tofacitinib in Patients With Prurigo Nodularis Tofacitinib 5 MG - Prurigo Nodularis, Itch | Not applicable | Unknown | Second Affiliated Hospital, Zhejiang University, School of Medicine | 24 | 2024-05-01 | 2024-04-01 |
| 3T Therapy in the Treatment of MDA5-positive Dermatomyositis Tofacitinib 5 MG - Dermatomyositis | Phase 4 | Enrolling by invitation | Second Affiliated Hospital, Zhejiang University, School of Medicine | 133 | 2024-03-19 | 2024-06-03 |
| Effectiveness and Safety of Tofacitinib in Patients With Recalcitrant Frontal Fibrosing Alopecia : A Pilot Study Tofacitinib 5 MG - Frontal Fibrosing Alopecia, Lichen Planopilaris of Scalp | Not applicable | Completed | Institute of Dermatology, Thailand | 11 | 2023-11-29 | 2025-05-30 |
| ToFAcitinib in Early Active Axial SpondyloarThritis: Tofacitinib 5 MG - Axial Spondyloarthritis | Phase 4 | Recruiting | Charite University, Berlin, Germany | 104 | 2023-11-10 | 2024-11-26 |
| Baricitinib in the Treatment of Refractory Axial Spondyloarthritis Patients: A Comparison With Tofacitinib Baricitinib 2mg, Tofacitinib 5 mg - Spondyloarthritis, Axial | Phase 2 | Unknown | Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh | 184 | 2023-10-30 | 2023-12-21 |
| Comparison of Tofacitinib and Prednisolone in the Treatment of Active Takayasu's Arteritis Tofacitinib 5 MG, Prednisolone, Placebo of tofacitinib 5mg - Takayasu Arteritis | Phase 3 | Unknown | Chinese SLE Treatment And Research Group | 50 | 2023-01-20 | 2023-03-01 |
| Study to Evaluate Safety, Tolerability, and Efficacy of GS-5718 in Participants With Active Rheumatoid Arthritis Who Have an Inadequate Response to Disease-modifying Antirheumatic Drug(s) (bDMARDs) Treatment GS-5718, Placebo to match GS-5718, Tofacitinib 5 mg - Rheumatoid Arthritis | Phase 2 | Withdrawn | Gilead Sciences | 2022-07-01 | 2022-05-18 | |
| Comparison of Adalimumab and Tofacitinib in the Treatment of Active Takayasu Arteritis Adalimumab Injection, Tofacitinib 5 MG - Takayasu Arteritis | Phase 4 | Unknown | Chinese SLE Treatment And Research Group | 100 | 2022-01-05 | 2023-07-24 |
| Tofacitinib as a GC Sparing Agent for Polymyalgia Rheumatica Tofacitinib 5 MG - Polymyalgia Rheumatica, Effect of Drug | Phase 2 | Completed | RenJi Hospital | 14 | 2021-01-01 | 2022-09-15 |
| Safety And Efficacy Of Tofacitinib In Patients With Refractory Myasthenia Gravis: A Pilot Study Tofacitinib 5 MG - Myasthenia Gravis, Generalized | Early Phase 1 | Completed | Huashan Hospital | 19 | 2020-06-11 | 2025-09-16 |
| Efficacy and Safety of GSK3196165 Versus Placebo and Tofacitinib in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate GSK3196165 (Otilimab), Tofacitinib 5 mg, Placebo - Arthritis, Rheumatoid | Phase 3 | Completed | GlaxoSmithKline | 1537 | 2019-05-16 | 2024-03-27 |
| Dose-Ranging Study Of Tofacitinib In Adults With Active Ankylosing Spondylitis Tofacitinib 2 mg, Tofacitinib 5 mg, Tofacitinib 10 mg - Ankylosing Spondylitis | Phase 2 | Completed | Pfizer | 208 | 2013-04-01 | 2016-06-10 |
| Tofacitinib Bioequivalence Study Comparing Tablets And Capsules tofacitinib 10 mg, tofacitinib 5 mg - Healthy | Phase 1 | Completed | Pfizer | 50 | 2012-05-01 | 2012-07-10 |
Arthritis, Rheumatoid (3) · Axial Spondyloarthritis (2) · Spondylarthritis (2) · Takayasu Arteritis (2) · Cardiovascular Diseases (1) · Dermatomyositis (1) · Lichen Planus (1) · Myasthenia Gravis (1) · Polymyalgia Rheumatica (1) · Pruritus (1) · Spondylarthropathies (1) · Spondylitis (1) · Spondylitis, Ankylosing (1)
Chinese SLE Treatment And Research Group (2) · Pfizer (2) · Second Affiliated Hospital, Zhejiang University, School of Medicine (2) · Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh (1) · Charite University, Berlin, Germany (1) · Gilead Sciences (1) · GlaxoSmithKline (1) · Huashan Hospital (1) · Institute of Dermatology, Thailand (1) · RenJi Hospital (1) · Shaikh Zayed Hospital, Lahore (1)
China (7) · Germany (2) · Hungary (2) · Poland (2) · Russia (2) · Spain (2) · Bangladesh (1) · Canada (1) · Czechia (1) · India (1) · Italy (1) · Malaysia (1) · Pakistan (1) · Serbia (1) · Singapore (1)
Aflak Rasheed, FCPS (1) · Chinmanat Lekhavat, MD (1) · Denis Poddubbnyy, Prof. Dr. med. (1) · Maira Khalil, MBBS (1) · Masooma Hashmat, FCPS (1) · Samaresh Das, M B B S (1) · Ting Li, MD (1) · Xiaofeng Zeng, MD (1) · Xinping Tian, MD (1)
PMID 28130206, PMID 36138330, PMID 36604153, PMID 37331992, PMID 37909386, PMID 38696034, PMID 38825359, PMID 39636343, PMID 39695887, PMID 40078463